New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SHPG;JNJ;MRK;PFE;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
February 19, 2015
16:50 EDTSNYSanofi appoints Olivier Brandicourt CEO
Subscribe for More Information
14:49 EDTPFEWalgreens selected by Pfizer as one of pharmacies to dispense Ibrance
Subscribe for More Information
09:59 EDTSNYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Altisource Residential (RESI) upgraded to Neutral from Sell at Compass Point... Angie's List (ANGI) upgraded to Overweight from Equal-Weight at First Analysis... Barrick Gold (ABX) upgraded to Buy from Hold at TD Securities... British Land (BTLCY) upgraded to Buy from Hold at Societe Generale... Coach (COH) upgraded to Buy from Hold at Topeka... Fiat Chrysler (FCAU) upgraded to Outperform from Neutral at Exane BNP Paribas... Garmin (GRMN) upgraded at BofA/Merrill... Hologic (HOLX) upgraded to Buy from Hold at Canaccord... Iberdrola (IBDRY) upgraded to Neutral from Underweight at HSBC... KPN (KKPNY) upgraded to Neutral from Underperform at Exane BNP Paribas... Monster Worldwide (MWW) upgraded at Evercore ISI... Pharmacyclics (PCYC) upgraded to Buy from Neutral at Nomura... RPC, Inc. (RES) upgraded to Equal Weight from Underweight at Morgan Stanley... Sanofi (SNY) upgraded to Buy from Neutral at BofA/Merrill... Sasol (SSL) upgraded to Neutral from Underweight at HSBC... Tractor Supply (TSCO) upgraded at Oppenheimer... Valero (VLO) upgraded to Buy from Hold at Deutsche Bank... Weingarten Realty (WRI) upgraded to Neutral from Sell at UBS... Werner (WERN) upgraded on improving freight fundamentals at RBC Capital... diaDexus (DDXS) upgraded to Buy from Neutral at Ladenburg,
08:38 EDTMRKNewLink reports clinical development milestone achieved with Merck for rVSV-EBOV
NewLink Genetics (NLNK) announced that it had received notification from Merck (MRK) that the milestone event specified in the license and collaboration agreement between the two companies relating to the further development of the rVSV-EBOV, Ebola, vaccine candidate had been achieved. Under the terms of the agreement, NewLink Genetics will receive a payment of $20M in connection with the achievement of the milestone. The milestone pertains to the initiation of a key clinical trial for the vaccine.
07:12 EDTPFEWharton Health Care Club to hold a conference
Subscribe for More Information
06:21 EDTSNYSanofi upgraded to Buy from Neutral at BofA/Merrill
05:31 EDTSNYSanofi upgraded to Buy from Neutral at BofA/Merrill
February 18, 2015
16:46 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
12:36 EDTJNJAnalysts applaud cheaper than expected Boston Scientific settlement
Subscribe for More Information
12:31 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
07:41 EDTJNJSettlement 'a big win' for Boston Scientific, says Bernstein
Subscribe for More Information
07:12 EDTJNJBoston Scientific settlement should remove overhang, says Stifel
Subscribe for More Information
07:09 EDTJNJBoston Scientific payment to J&J well below expectations, says Piper Jaffray
Subscribe for More Information
February 17, 2015
18:06 EDTSHPGPaulson & Co gives quarterly update on stakes
Subscribe for More Information
16:29 EDTJNJ Boston Scientific announces settltement of merger agreement lawsuit
Subscribe for More Information
15:36 EDTPFETianyin JCM plans for FDA certification process
Tianyin Pharmaceutical (TPI) updated on the business and development at its Jiangchuan Macrolide Facility, or JCM, active pharmaceutical ingredients operation. In addition to JCM's certification at India, along with other international clients located at Bangladesh, Philippines and Iran on import status, TPI plans for FDA certification process at its JCM facility in order to service international clients such as Pfizer's (PFE) and their subsidiaries in China, the company said. "This is expected to translate to further demand for JCM's macrolide API business in both the domestic and international markets," Tianyin stated.
11:38 EDTSNYGenzyme reports publication of ENGAGE registration study results
Subscribe for More Information
10:01 EDTPFECVS says PCSK9 inhibitors could cost system $150B annually
Subscribe for More Information
09:12 EDTSHPGShire multiple poised to expand, says SunTrust
SunTrust believes that Shire's rare disease unit will account for 40% of its 2020 sales, versus the company's estimate of about 35%. As a result, the firm expects the company's multiple to "re-rate." The firm thinks that the company's long-term growth outlook is underappreciated, and it keeps a $262 price target and Buy rating on the shares.
07:04 EDTJNJGTx names Robert Wills as executive chairman
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use